Difference between revisions of "Etoposide (Vepesid)"
m |
m |
||
| Line 3: | Line 3: | ||
==General information== | ==General information== | ||
Class/mechanism: Topoisomerase II inhibitor. Causes DNA strand breaks by interacting with DNA-topoisomerase II or by forming free radicals. Causes arrest at the G2 portion of the cell cycle, with dose dependent effects: at high concentrations, cells entering mitosis undergo lysis; at low concentrations, cells are inhibited from entering prophase.<ref name="insert">[http://packageinserts.bms.com/pi/pi_etopophos.pdf Etoposide (Vepesid) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/etoposide.pdf Etoposide (Vepesid) package insert (locally hosted backup)]</ref> | Class/mechanism: Topoisomerase II inhibitor. Causes DNA strand breaks by interacting with DNA-topoisomerase II or by forming free radicals. Causes arrest at the G2 portion of the cell cycle, with dose dependent effects: at high concentrations, cells entering mitosis undergo lysis; at low concentrations, cells are inhibited from entering prophase.<ref name="insert">[http://packageinserts.bms.com/pi/pi_etopophos.pdf Etoposide (Vepesid) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/etoposide.pdf Etoposide (Vepesid) package insert (locally hosted backup)]</ref> | ||
| − | <br>Route: IV | + | <br>Route: IV, PO |
<br>Extravasation: [[irritant]] | <br>Extravasation: [[irritant]] | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information<ref name="insert"></ref> | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> |
==Patient drug information== | ==Patient drug information== | ||
Revision as of 04:43, 10 May 2012
Also known as VP-16.
General information
Class/mechanism: Topoisomerase II inhibitor. Causes DNA strand breaks by interacting with DNA-topoisomerase II or by forming free radicals. Causes arrest at the G2 portion of the cell cycle, with dose dependent effects: at high concentrations, cells entering mitosis undergo lysis; at low concentrations, cells are inhibited from entering prophase.[1][2]
Route: IV, PO
Extravasation: irritant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
- Etoposide (Vepesid) patient drug information (Chemocare)[3]
- Etoposide (Vepesid) patient drug information (UpToDate)[4]